Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

Md. County's Model Health Program For The Uninsured Faces Some Obstacles
One Maryland county"s tiny new health care programs for the uninsured could be a model for providing care nationwide, National Public Radio says in an ongoing series. The program is cheap, effective and heavy on preventive care, Howard County"s health commissioner, Dr. Peter Beilenson says. The program, called Healthy Howard, provides care for families of four earning up to $66,000 a year, and patients are required to pay $50 to $85 a month. But some of the enrollees are running into trouble.
generic viagra online
Eye Movements Of Parkinson's Disease Patients During Sentence Comprehension Support Subcortical Role In Processing Syntax
The study of the neural basis of language has largely focused on regions in the cortex - the outer brain layers thought by many researchers to have expanded during human evolution. Research at Brown University"s Department of Cognitive and Linguistic Sciences, reported in the September Issue of Cortex, published by Elsevier, adds to evidence that deeper, subcortical regions are also critical by pinpointing when Parkinson"s disease patients have difficulty while processing grammatically complex sentences. In Parkinson"s disease, degeneration of subcortical dopamine-secreting neurons leads not only to motor symptoms but often also to cognitive deficits.
News of the day
Reform Debate Circles Back To Costs, And How To Pay For Them
In the White House"s pitches for health care reform, controlling costs has replaced universal coverage as the leading imperative to overhaul the system. A top White House economist, Christina Romer, said in a public appearance Monday, "Good health care reform is good economic policy," the San Francisco Chronicle reports. "Fixing what"s wrong with our health care system is no longer a luxury we hope to achieve - it"s a necessity we cannot postpone any longer" (Abate, 6/9).
Medical Devices

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323

UCB and Biogen Idec announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted. CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis. For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects an estimated 1.1 - 2.5 million people worldwide. Although the exact cause is unknown, MS occurs as a result of loss of the protective outer coating on nerves in the brain and spinal cord. Deterioration in the way that messages are transmitted around the body leads to loss of movement and other body functions. Symptoms of MS can include vision problems, loss of balance, numbness, difficulty walking and paralysis. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec"s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009